HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IMNM
Immunome, Inc.
There isn't enough reported data to score IMNM yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IMNM Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
IMNM's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IMNM PE Valuation
IMNM has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IMNM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IMNM's losses to grow, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IMNM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.65 | +$0.13 |
| Q2 2026 | -$2.54 | +$0.37 |
| Q1 2026 | -$2.39 | +$0.62 |
| Q4 2025 | -$2.43 | +$2.57 |
| Q3 2025 | -$2.78 | +$5.32 |
| Q2 2025 | -$2.91 | +$4.77 |
| Q1 2025 | -$3.01 | +$4.53 |
| Q4 2024 | -$5.00 | +$0.38 |
IMNM has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IMNM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
IMNM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $4M | +70% |
| Q1 2025 | $2.9M | +184% |
| Q4 2024 | $2.7M | -28% |
| Q3 2024 | $2.9M | -18% |
| Q2 2024 | $2.4M | -45% |
| Q1 2024 | $1M | -56% |
IMNM's revenue has slid since its 2023 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -1158% | +535 points |
| Q1 2025 | -1526% | +11332 points |
| Q4 2024 | -3030% | -556 points |
| Q3 2024 | -1736% | -1606 points |
| Q2 2024 | -1692% | -1557 points |
| Q1 2024 | -12857% | -12668 points |
| Q4 2023 | -2474% | N/A |
| Q3 2023 | -130% | N/A |
IMNM's operating margin was −1158% last quarter, up 535 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IMNM on cash generation, producing positive trailing cash flow while its opponent burns cash.
IMNM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$61.2M | -$19.6M |
| Q2 2026 | -$63.9M | -$13.6M |
| Q1 2026 | -$61.6M | -$4.9M |
| Q4 2025 | -$52M | -$8.8M |
| Q3 2025 | -$41.6M | -$5.9M |
| Q2 2025 | -$50.3M | -$24.6M |
| Q1 2025 | -$56.7M | -$43.4M |
| Q4 2024 | -$43.2M | -$25.4M |
IMNM has burned cash in almost every quarter: −$239M over the past year, against −$192M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IMNM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IMNM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +292K shares |
| 1 year | +31% | +26.6M shares |
| 3 years | +836% | +101M shares |
| 5 years | +10090% | +112M shares |
IMNM has 114M diluted shares, up 31% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IMNM Net Leverage
IMNM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IMNM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.7 | Neutral |
| Stochastic | 15.6 | Oversold |
IMNM's weekly RSI is 42 (neutral) and its Stochastic is 16 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IMNM PE vs Healthcare Sector
IMNM has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IMNM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.0 | 1.5% below |
| 20 week MA | $22.5 | 17% below |
| 50 week MA | $21.9 | 15% below |
| 100 week MA | $16.2 | 15% above |
| 200 week MA | $13.7 | 36% above |
IMNM has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IMNM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.5 | $10.2 | -24% |
| 2021 | $10.2 | $16.5 | +62% |
| 2022 | $16.5 | $3.15 | -81% |
| 2023 | $3.15 | $10.7 | +240% |
| 2024 | $10.7 | $10.5 | -1.5% |
| 2025 | $10.5 | $21.7 | +106% |
| 2026 YTD | $21.7 | $18.7 | -14% |
IMNM has the edge over HIMS on returns for 2026, with the stronger performance.